Last reviewed · How we verify
NCT06025773
A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121
Phase 1 trial testing Lansoprazole 15 mg in Gastro Esophageal Reflux in 24 participants. Completed in 19 April 2024.
19 April 2024
Quick facts
| Lead sponsor | Addpharma Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 15 September 2023 |
| Primary completion | 19 April 2024 |
| Estimated completion | 19 April 2024 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Lansoprazole 15 mg — full drug profile →
- Lansoprazole 15mg/Calcium carbonate 600mg — full drug profile →
Conditions studied
- Gastro Esophageal Reflux — all drugs for Gastro Esophageal Reflux →
Sponsor
Addpharma Inc. — full company profile →
Who can join
19 and older, any sex, with Gastro Esophageal Reflux. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-212-A in healthy subjects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06025773
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Lansoprazole 15 mg
Trials testing the same drug.
- NCT05820048 — The Efficacy and Safty of Proton Pump Inhibitor (Lansoprazole) · Phase 4 · unknown
- NCT04784910 — Study to Evaluate the Efficacy and Safety of DWP14012 in Prevention of NSAIDs Induced Peptic Ulcer · Phase 3 · completed
- NCT04341428 — Study to Evaluate the Efficacy and Safety of DWP14012 on Maintaining Healing in Subjects With Healed Erosive Esophagitis · Phase 3 · unknown
Other recruiting trials for Gastro Esophageal Reflux
Currently open trials in the same condition.
- NCT07482969 — Prevalence of Symptomatic Gastroesophageal Reflux Disease in Czech Children (Czech GERDKids) · recruiting
- NCT05455359 — Gastrointestinal Dysmotility on Aspiration Risk · Phase 4 · recruiting
- NCT07131397 — The Effect of Inspiratory Muscle Training in People With Gastroesophageal Reflux Disease · NA · recruiting
- NCT06564558 — The Effect of Postural Correction On Gastroesophageal Reflux Disease · NA · recruiting
- NCT05570448 — Anti-Reflux Endoscopic TX Using APC (AREA) in GERD Patients: (The AREA Study) · NA · recruiting
Other Addpharma Inc. trials
Trials by the same sponsor.
- NCT07444385 — A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Subjects · Phase 1 · recruiting
- NCT07312799 — Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322 · Phase 1 · not yet recruiting
- NCT07385235 — Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151' · Phase 1 · recruiting
- NCT07312773 — A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-231A and AD-231B and AD-231C · Phase 1 · not yet recruiting
- NCT06884085 — A Study to Compare to PK Characteristics and Safety Profiles Between AD-227 and Co-administration of AD-227A and AD-227B · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06025773 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Addpharma Inc.
- Last refreshed: 1 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06025773.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing